Pfizer Inc. (PFE)

36.46
NYSE : Health Technology
Prev Close 36.46
Day Low/High 36.36 / 36.68
52 Wk Low/High 33.97 / 46.47
Avg Volume 23.93M
Exchange NYSE
Shares Outstanding 5.53B
Market Cap 201.66B
EPS 1.90
P/E Ratio 16.42
Div & Yield 1.44 (3.89%)

Latest News

Pfizer Presents Positive Phase 3 Data At The 28th Congress Of The European Academy Of Dermatology And Venereology For Abrocitinib In Moderate To Severe Atopic Dermatitis

Pfizer Presents Positive Phase 3 Data At The 28th Congress Of The European Academy Of Dermatology And Venereology For Abrocitinib In Moderate To Severe Atopic Dermatitis

Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to severe atopic dermatitis (AD).

Akcea Stocks Soars on Pfizer Licensing Agreement

Akcea Stocks Soars on Pfizer Licensing Agreement

Akcea shares soar after the company announces a licensing agreement with Pfizer for its treatment for people with certain cardiovascular and metabolic diseases.

Dow Finishes Higher as Wall Street Bounces Back, Probability Climbs for Rate Cut

Dow Finishes Higher as Wall Street Bounces Back, Probability Climbs for Rate Cut

Stocks finish higher after falling earlier in the session following a weak reading on U.S. services sector activity.

Pfizer Presents Interim Analysis Results From Phase 3 BEACON CRC Trial Of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) And Cetuximab For The Treatment Of BRAFV600E-Mutant Metastatic Colorectal Cancer

Pfizer Presents Interim Analysis Results From Phase 3 BEACON CRC Trial Of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) And Cetuximab For The Treatment Of BRAFV600E-Mutant Metastatic Colorectal Cancer

Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI ® (encorafenib), MEKTOVI ® (binimetinib), and cetuximab (BRAFTOVI Triplet), in patients with advanced...

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug

Pfizer shares edged higher Friday after the company posted promising results from trials of a drug it's developing to treat patients with moderate-to-severe eczema.

Pfizer Inc. Awards "Golden Tickets" To Neutrolis And Mediar Therapeutics

Pfizer Inc. Awards "Golden Tickets" To Neutrolis And Mediar Therapeutics

Pfizer Inc. and LabCentral announced that Pfizer has selected Neutrolis and Mediar Therapeutics are the winners of this year's Pfizer Golden Ticket Program.

Ian Read To Retire As Executive Chairman Of Pfizer's Board Of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman

Ian Read To Retire As Executive Chairman Of Pfizer's Board Of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc.

Pfizer Announces Positive Top-Line Results From Second Pivotal Phase 3 Study Of Investigational Oral JAK1 Candidate, Abrocitinib, In Patients Aged 12 And Older With Moderate To Severe Atopic Dermatitis

Pfizer Announces Positive Top-Line Results From Second Pivotal Phase 3 Study Of Investigational Oral JAK1 Candidate, Abrocitinib, In Patients Aged 12 And Older With Moderate To Severe Atopic Dermatitis

Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate...

Pfizer Declares Fourth-Quarter 2019 Dividend

Pfizer Declares Fourth-Quarter 2019 Dividend

The Board of Directors of Pfizer Inc. today declared a 36-cent fourth-quarter 2019 dividend on the company's common stock, payable December 2, 2019, to holders of the Common Stock of record at the close of business on November 8, 2019.

Pfizer Presents New Evidence Of IBRANCE® (palbociclib) Effectiveness In HR , HER2- Metastatic Breast Cancer Patients In Four Real-World Studies At ESMO Congress 2019

Pfizer Presents New Evidence Of IBRANCE® (palbociclib) Effectiveness In HR , HER2- Metastatic Breast Cancer Patients In Four Real-World Studies At ESMO Congress 2019

Pfizer Inc. (NYSE: PFE) today announced the presentation of four IBRANCE ® (palbociclib) real-world analyses.

Exact Sciences Lifted to Buy at Benchmark on Wider Cologuard-Use Approval

Exact Sciences Lifted to Buy at Benchmark on Wider Cologuard-Use Approval

Analyst Bruce Jackson likes the prospects for the producer of a DNA-based colon-cancer-screening test for use at home.

Got a Minute? Jim Cramer Breaks Down the Markets and Ticker Tape

Got a Minute? Jim Cramer Breaks Down the Markets and Ticker Tape

Jim Cramer's breaking down the ticker tape for investors.

Pfizer Invites Public To View And Listen To Webcast Of October 29 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of October 29 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

Pfizer Announces Positive Preliminary Results From A Proof-of-Concept Phase 2 Study (B7471003) Of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Otitis Media In Healthy Infants

Pfizer Announces Positive Preliminary Results From A Proof-of-Concept Phase 2 Study (B7471003) Of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Otitis Media In Healthy Infants

Pfizer Inc. (NYSE: PFE) announced today positive preliminary results following administration of three doses in a four-dose series for a Proof-of-Concept Phase 2 study (B7471003) to assess safety and immunogenicity of its 20-valent pneumococcal conjugate...

Have the FAANG Stocks Fallen From Favor?

Have the FAANG Stocks Fallen From Favor?

Mark Hulbert takes a look at the stocks most favored by the top-performing newsletters.

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Chief Financial Officer and Executive Vice President, Global Supply and Business Operations, at the Morgan Stanley 17 th Annual Global...

Dow Ends Higher as Wall Street Gets Boost From Gains in Energy Sector

Dow Ends Higher as Wall Street Gets Boost From Gains in Energy Sector

Stocks finish higher as energy stocks rise on the back of higher oil prices.

Stocks End Down as Recession Worries Resurface, Trade Concerns Remain

Stocks End Down as Recession Worries Resurface, Trade Concerns Remain

Stocks finish down as recession worries again emerge and as investors monitor U.S. and China trade negotiations.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Union Pacific, Pfizer, Merck, AbbVie: 'Mad Money' Lightning Round

Union Pacific, Pfizer, Merck, AbbVie: 'Mad Money' Lightning Round

Jim Cramer takes a look at Union Pacific, Pfizer, Merck, AbbVie, Teva Pharmaceuticals, ABM Industries, Schlumberger and more.

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.

Pfizer Invests Half Billion Dollars To Advance State-of-the-Art Gene Therapy Facility In Sanford, North Carolina

Pfizer Invests Half Billion Dollars To Advance State-of-the-Art Gene Therapy Facility In Sanford, North Carolina

Pfizer announced today an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina.

Teva's Generic EpiPen Jr Is Now Available for $300

Teva's Generic EpiPen Jr Is Now Available for $300

There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer.

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #20 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #299 spot.

GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails

GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails

The company announces that rivipansel, which was developed in partnership with Pfizer, didn't meet primary or secondary endpoints.

Pfizer Announces Phase 3 Top-Line Results For Rivipansel In Patients With Sickle Cell Disease Experiencing A Vaso-Occlusive Crisis

Pfizer Announces Phase 3 Top-Line Results For Rivipansel In Patients With Sickle Cell Disease Experiencing A Vaso-Occlusive Crisis

Pfizer Inc. (NYSE:PFE) announced today that the Phase 3 R ivipansel (GMI-1070): E valuating S afety, E fficacy and T ime to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints.

Pfizer Announces Closing Of Joint Venture With GlaxoSmithKline To Create A Premier Global Consumer Healthcare Company

Pfizer Announces Closing Of Joint Venture With GlaxoSmithKline To Create A Premier Global Consumer Healthcare Company

Pfizer Inc. (NYSE: PFE) today announced the closing of its joint venture with GlaxoSmithKline plc (NYSE: GSK) to combine the parties' respective consumer healthcare businesses to create the world's largest over-the-counter (OTC) business with robust...

TheStreet Quant Rating: B (Buy)